C R Bard Acquires Angiomed

9 October 1994

US company C R Bard has acquired Angiomed, a German manufacturer of specialty health care products. Terms of the deal were not disclosed. Bard will consolidate its current Germany operations, which are based in Munich, at Angiomed's headquarters in Karlsruhe, where nearly 400 Angiomed employees are based.

Angiomed had 1993 revenues of $40 million, with most of its sales generated in Germany. Bard reported 1993 revenues of $970.8 million and has said it expects some decline in earnings per share for the fourth quarter.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight